Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Recruiting now · Not applicable

Conditions studied: Breast Cancer With Low to Intermediate HER2 Expression

In brief

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).

Key facts

Study ID

NCT07630402

Run by

University of Rochester

People needed

20

Starts

2025-11-17

Expected to finish

2031-06-30

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older, up to 79. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female sex, age 18-79 years.
• Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
• Baseline LVEF ≥ 55 % by 2-D echocardiography.
• Ability to provide informed consent.

You may not qualify if…

• Prior HF, myocardial infarction, or cardiomyopathy.
• Atrial fibrillation or significant valvular heart disease.
• Cumulative anthracycline dose ≥ 250 mg/m².
• Pregnancy or lactation.
• Inability to comply with study procedures.

Where it is running

• Wilmot Cancer Center — Rochester, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.